{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:57:03Z","timestamp":1786978623990,"version":"build-2736575974"},"reference-count":49,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T00:00:00Z","timestamp":1632873600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Veterinary Record"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Enflicoxib is a new COX\u20102 selective NSAID intended for the treatment of pain and inflammation associated with canine osteoarthritis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A prospective, multisite, blinded, randomised, controlled, parallel\u2010group field study was performed to determine the efficacy and safety of enflicoxib in canine osteoarthritis. A total of 242 dogs were randomised to receive enflicoxib at 4 or 2\u00a0mg\/kg, mavacoxib at 2\u00a0mg\/kg or placebo, orally. Enflicoxib and placebo were administered once weekly from day 0 to day 35. Mavacoxib was administered on D0 and day 14. Veterinarians assessed efficacy with a numerical rating scale and owners used the Canine Brief Pain Inventory.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After 6 weeks, enflicoxib at 4\u00a0mg\/kg showed the highest percentage of responders as assessed by the veterinarians (68%) and the owners (84%), followed by mavacoxib (62and 83%, respectively), and enflicoxib at 2\u00a0mg\/kg (57 and 80%, respectively). All treatments reached statistical significance versus placebo, which obtained success rates of 37% and 53%, respectively. No differences in the incidence of adverse reactions were detected among the different groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Enflicoxib administered weekly for 6 weeks, at 4\u00a0mg\/kg PO with an initial loading dose of 8\u00a0mg\/kg, is efficacious and safe for the treatment of canine osteoarthritis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/vetr.949","type":"journal-article","created":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T02:26:01Z","timestamp":1632968761000},"source":"Crossref","is-referenced-by-count":15,"title":["Efficacy and safety of enflicoxib for treatment of canine osteoarthritis: A 6\u2010week randomised, controlled, blind, multicentre clinical trial"],"prefix":"10.1002","volume":"191","author":[{"given":"Marta","family":"Salichs","sequence":"first","affiliation":[{"name":"Ecuphar Veterinaria SLU (Animalcare Group)  Avgda. R\u00edo de Janeiro 60 \u2010 66, planta 13 Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lloren\u00e7","family":"Badiella","sequence":"additional","affiliation":[{"name":"Servei d'Estad\u00edstica Aplicada Universitat Aut\u00f2noma de Barcelona, Bellaterra  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patxi","family":"Sarasola","sequence":"additional","affiliation":[{"name":"Ondax Scientific SL  Hondarribia Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5440-7699","authenticated-orcid":false,"given":"Josep","family":"Homedes","sequence":"additional","affiliation":[{"name":"Ecuphar Veterinaria SLU (Animalcare Group)  Avgda. R\u00edo de Janeiro 60 \u2010 66, planta 13 Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,9,29]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00221\u2010009\u20101782\u20109"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rehab.2016.07.004"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.2460\/javma.2005.226.387"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.2460\/javma.229.5.690"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0195\u20105616(97)50076\u20103"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar3373"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tvjl.2004.08.014"},{"key":"e_1_2_11_9_1","first-page":"287","article-title":"Treatment options for osteoarthritis","volume":"11","author":"Singh G","year":"2003","journal-title":"Surg Technol Int"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.2460\/javma.230.4.514"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939\u20101676.2012.00901.x"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.4314\/ovj.v7i1.6"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/vr.164.14.418"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/vr.d1021"},{"key":"e_1_2_11_15_1","doi-asserted-by":"crossref","unstructured":"MansaS Palm\u00e9rE Gr\u00f8ndahlC L\u00f8naasL NymanG.Long\u2010term treatment with carprofen of 805 dogs with osteoarthritis. Vet Rec.2007;160(13):427\u201330.https:\/\/doi.org\/10.1136\/vr.160.13.427. PMID: 17400900.","DOI":"10.1136\/vr.160.13.427"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/vr.c97"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tvjl.2015.07.025"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/vr.152.11.323"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.2460\/ajvr.68.3.258"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvim.12127"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/vr.102435"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/vr.102352"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1748\u20105827.1999.tb03781.x"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.2460\/javma.2005.226.567"},{"key":"e_1_2_11_25_1","volume-title":"Compliance: Taking Quality Care to the Next Level; a Report of the 2009 AAHA Compliance Follow\u2010Up Study","author":"American Animal Hospital Association","year":"2009"},{"key":"e_1_2_11_26_1","unstructured":"Cendr\u00f3sJM SalichsM SampAK EncinaG VelaJM HomedesJ.Pharmacology of enflicoxib a new coxib drug: dose determination by efficacy and pharmacokinetic guided approach for the treatment of osteoarthritis in dogs based on an acute arthritis induction model. DVG Vet Congress 18\u201320 November 2021 Berlin (Accepted)."},{"key":"e_1_2_11_27_1","unstructured":"VICH (2000) International Co\u2010operation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products Good Clinical Practice June 2000 effective 01 July 2001."},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1292\/jvms.11\u20100529"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/vr.102397"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/vms3.182"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/vr.159.17.547"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1136\/vr.d1456"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.2460\/ajvr.68.6.631"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.2460\/javma.233.8.1278"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvp.12995"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102885.2010.01165.x"},{"key":"e_1_2_11_37_1","unstructured":"VICH 2007 International Co\u2010operation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products GL24 on pharmacovigilance of veterinary medicinal products: management of adverse event reports (AERs) October 2007 for implementation by 31st December 2015."},{"key":"e_1_2_11_38_1","unstructured":"EMA 2018. EMA\/CVMP\/PhVWP\/10418\/2009\u2010Rev.10 Committee for Medicinal Products for Veterinary Use (CVMP) Combined VeDDRA list of clinical terms for reporting suspected adverse reactions in animals and humans to veterinary medicinal products 21 June 2018."},{"key":"e_1_2_11_39_1","unstructured":"EMA 2013 EMA\/CVMP\/PhVWP\/552\/2003 \u2013 Rev.1 Committee for Medicinal Products for Veterinary Use (CVMP) Recommendation on harmonising the approach to causality assessment for adverse events to veterinary medicinal products. 10 October 2013."},{"key":"e_1_2_11_40_1","unstructured":"NTA 2011. VOLUME 9B of The Rules Governing Medicinal Products in the European Union \u2013 Guidelines on Pharmacovigilance for Medicinal Products for Veterinary Use. October 2011."},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvim.13948"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.2460\/ajvr.74.12.1467"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvim.12004"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1593\/tlo.08160"},{"issue":"3","key":"e_1_2_11_45_1","first-page":"237","article-title":"Guidelines for safe and effective use of NSAIDs in dogs","volume":"6","author":"Lascelles BD","year":"2005","journal-title":"Vet Ther"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cvsm.2012.04.007"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467\u20102995.2011.00675.x"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12917\u2010021\u201002910\u20100"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.2460\/ajvr.72.5.601"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvp.12185"}],"container-title":["Veterinary Record"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/vetr.949","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/vetr.949","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bvajournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/vetr.949","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T09:00:46Z","timestamp":1761642046000},"score":1,"resource":{"primary":{"URL":"https:\/\/bvajournals.onlinelibrary.wiley.com\/doi\/10.1002\/vetr.949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,29]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["10.1002\/vetr.949"],"URL":"https:\/\/doi.org\/10.1002\/vetr.949","archive":["Portico"],"relation":{},"ISSN":["0042-4900","2042-7670"],"issn-type":[{"value":"0042-4900","type":"print"},{"value":"2042-7670","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,29]]},"article-number":"e949"}}